Juniper Biologics, a science-led healthcare company focused on researching, developing and commercializing novel therapies has acquired $600million USD to supply the world’s first cell-mediated gene therapy to an estimated 300 million patients in Asia Pacific, Middle East and Africa. They announced that that they have got the licensing rights to develop and commercialize TG-C LD (Tissue Gene-C low dose) for the treatment of knee osteoarthritis. The $600 million USD licensing deal was signed with Kolon Life Science. This is the second acquisition by Juniper Biologics in as many months. Under the terms of the partnership, Juniper Biologics will be responsible for developing and commercializing TG-C LD to medical professionals and hospitals within Asia Pacific, Middle East and Africa.
TG-C LD is a non-surgical treatment that has been the world’s first cell-mediated gene therapy for osteoarthritis of the knee. Osteoarthritis is the most common form of the knee. It occurs when flexible tissue at the end of bones wears down. The wearing down of the tissue at the end of the bones which is cartilage, occurs gradually and worsens over time.
It is estimated that osteoarthritis is the eleventh leading cause of disability with an estimated of 300 million patients in Asia Pacific, Middle East and Africa. TG- C LD targets knee osteoarthritis through a single intra-articular injection. Clinical trials held in the United States and abroad has shown results of pain relief and increased mobility. The TG- C LD product is being developed in two dosages. One is TG-C which is developed in the United States by Kolon Tissue Gene and another one is TG-C LD, which is developed in Korea by Kolon Life Science.
